Skip to main content
Fig. 9 | Journal of Neuroinflammation

Fig. 9

From: Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy

Fig. 9

PK2 serum levels. PK2 serum levels were measured by ELISA 14 days after the first BTZ administration, before starting the PC1 treatment (CTR and BTZ groups), and at the end of the BTZ/BTZ + PC1 protocol (CTR, BTZ, BTZ + PC1 groups). Data represent mean ± SD of 6 mice/group. At day 14, statistical analysis was performed by means of t test while at day 28 by means of one-way ANOVA followed by Bonferroni’s post-test.*p < 0.05, **p < 0.01 vs CTR; °°°p < 0.001 vs BTZ day 28

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094